{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": "Liu_et_al.__2024_",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 2
  },
  "completeness_stats": {
    "existing_evidence": 2,
    "new_evidence_found": 2,
    "total_evidence": 4
  },
  "verified_evidence": [
    {
      "id": 1,
      "quote": "a cell culture based influenza vaccine (Flucelvax Quadrivalent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quadrivalent by Sanofi Pasteur, RIV4). RIV4 contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain).",
      "supports_claim": true,
      "explanation": "The quote appears on page 3 of the document, though with some minor OCR artifacts and line breaks. The relevant passage is: 'a cell culture based influenza vaccine (Flucelvax Quadrivalent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quadrivalent by SanofiPasteur, RIV4). RIV4 contains 3 times the i d 45 HA/d / ...d IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain).' This matches the factual content of the quote to verify: it states that RIV4 (Flublok) contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain).. The quote directly supports the first part of the claim by explicitly stating that Flublok (RIV4) contains 3 times the hemagglutinin (HA) antigen content per strain compared to standard-dose flu vaccines (IIV4 and ccIIV4). The second part of the claim, regarding greater immunogenicity, is supported elsewhere in the document (e.g., 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4'), but the quote itself is sufficient to substantiate the antigen content comparison.",
      "presence_explanation": "The quote appears on page 3 of the document, though with some minor OCR artifacts and line breaks. The relevant passage is: 'a cell culture based influenza vaccine (Flucelvax Quadrivalent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quadrivalent by SanofiPasteur, RIV4). RIV4 contains 3 times the i d 45 HA/d / ...d IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain).' This matches the factual content of the quote to verify: it states that RIV4 (Flublok) contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain).",
      "support_explanation": "The quote directly supports the first part of the claim by explicitly stating that Flublok (RIV4) contains 3 times the hemagglutinin (HA) antigen content per strain compared to standard-dose flu vaccines (IIV4 and ccIIV4). The second part of the claim, regarding greater immunogenicity, is supported elsewhere in the document (e.g., 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4'), but the quote itself is sufficient to substantiate the antigen content comparison.",
      "original_relevance": "This quote explicitly states that Flublok (RIV4) contains 3 times the hemagglutinin (HA) antigen content per strain compared to standard-dose flu vaccines (IIV4 and ccIIV4), directly supporting the first part of the claim."
    },
    {
      "id": 2,
      "quote": "In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3N2) virus than ccIIV4 and IIV4.",
      "supports_claim": true,
      "explanation": "The quote 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3N2) virus than ccIIV4 and IIV4.' appears in the document, specifically in the following passage: 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.' The wording and factual content are essentially identical, with only minor formatting differences (e.g., spacing, line breaks).. The quote directly supports the claim that Flublok (RIV4) is linked to greater immunogenicity compared to standard-dose flu vaccines (IIV4 and ccIIV4), as it states that RIV4 induced higher neutralizing and total HA head binding antibodies to cell-A (H3N2) virus. This is a direct measure of immunogenicity. The document also confirms elsewhere that RIV4 contains 3 times the HA antigen content of IIV4 and ccIIV4, thus linking the higher HA content to the observed greater immunogenicity.",
      "presence_explanation": "The quote 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3N2) virus than ccIIV4 and IIV4.' appears in the document, specifically in the following passage: 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.' The wording and factual content are essentially identical, with only minor formatting differences (e.g., spacing, line breaks).",
      "support_explanation": "The quote directly supports the claim that Flublok (RIV4) is linked to greater immunogenicity compared to standard-dose flu vaccines (IIV4 and ccIIV4), as it states that RIV4 induced higher neutralizing and total HA head binding antibodies to cell-A (H3N2) virus. This is a direct measure of immunogenicity. The document also confirms elsewhere that RIV4 contains 3 times the HA antigen content of IIV4 and ccIIV4, thus linking the higher HA content to the observed greater immunogenicity.",
      "original_relevance": "This quote provides direct evidence that the higher HA content in Flublok (RIV4) is linked to greater immunogenicity, as measured by higher neutralizing and HA head binding antibody responses compared to standard-dose vaccines."
    }
  ],
  "new_evidence": [
    {
      "id": "comp_1",
      "quote": "For A (H3 N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody in the 45\u221264 years group, it also significantly increased the quantity of the total A (H3 N2) cell HA head binding antibodies (Fig. 4 A, Fig. S1 A).",
      "relevance_explanation": "This quote directly supports the claim that Flublok (RIV4) is linked to greater immunogenicity compared to standard-dose flu vaccines, specifically by showing a significant increase in total HA head binding antibodies after RIV4 vaccination.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "In year 2, among the 7 repeat vaccination arms (IIV4-IIV4, IIV4-ccIIV4, IIV4-RIV4, RIV4-ccIIV4, RIV4-RIV4, ccIIV4-ccIIV4 and ccIIV4-RIV4), repeat vaccination with either RIV4 or ccIIV4 further improved antibody responses to circulating viruses compared to IIV4.",
      "relevance_explanation": "This quote provides evidence that RIV4 (Flublok) is associated with greater immunogenicity than standard-dose IIV4, as repeat vaccination with RIV4 led to improved antibody responses.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "model_used": "gpt-4.1"
}